Swalih P Ahmed

Mr. Swalih P Ahmed

Aligarh Muslim Univerisity
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Swalih P AhmedSwalih P Ahmed
Swalih P Ahmed
JCJavier Castresana
Javier Castresana
Mehdi H ShahiMehdi H Shahi
Mehdi H Shahi
Glioblastoma (GB) is one of the most common types of lethal brain tumors. Although several treatment options are available including surgery, along with adjuvant chemo and radiotherapy, the disease has a poor prognosis and patients generally die within 14 months of diagnosis. GB is chemo and radio resistant. Thus, there is a critical need for new insights into GB treatment to increase the chance of therapeutic success. This is why microRNA (miRNA) is being potentially considered in the diagnosis and treatment of glioblastoma. The objective of our review is to provide a holistic picture of GB up-regulated and down-regulated miRNA, in relationship with the expression of other genes, cell signaling pathways, and their role in GB diagnosis and treatment. MiRNA treatment is being considered to be used against GB together with radiotherapy and chemotherapy. Moreover, the use of miRNA as a diagnostic tool has also begun. Knowing that miRNAs are isolated in almost all human body fluids and that there are more than 3000 miRNAs in the human genome, plus the fact that each miRNA controls hundreds of different mRNAs, there is still much study needed to explore how miRNAs relate to GB for its proliferation, progression, and inhibition.

6 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
Swalih P AhmedSwalih P Ahmed
Swalih P Ahmed
JCJavier Castresana
Javier Castresana
Mehdi H ShahiMehdi H Shahi
Mehdi H Shahi
Central nervous system tumors are a leading cause of cancer-related death in children and adults, with medulloblastoma (MB) and glioblastoma (GBM) being the most prevalent malignant brain tumors, respectively. Despite tremendous breakthroughs in neurosurgery, radiation, and chemotherapeutic techniques, cell heterogeneity and various genetic mutations impacting cell cycle control, cell proliferation, apoptosis, and cell invasion result in unwanted resistance to treatment approaches, with a 5-year survival rate of 70–80% for medulloblastoma, and the median survival time for patients with glioblastoma is only 15 months. Developing new medicines and utilizing combination medications may be viewed as excellent techniques for battling MB and GBM. Circular RNAs (circRNAs) can affect cancer-developing processes such as cell proliferation, cell apoptosis, invasion, and chemoresistance in this regard. As a result, several compounds have been introduced as prospective therapeutic targets in the fight against MB and GBM. The current study aims to elucidate the fundamental molecular and cellular mechanisms underlying the pathogenesis of GBM in conjunction with circRNAs. Several mechanisms were examined in detail, including PI3K/Akt/mTOR signaling, Wnt/-catenin signaling, angiogenic processes, and metastatic pathways, in order to provide a comprehensive knowledge of the involvement of circRNAs in the pathophysiology of MB and GBM.

7 October 2022 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
SFShirin Farheen
Shirin Farheen
Swalih P AhmedSwalih P Ahmed
Swalih P Ahmed
MMMubeena Mariyath P. M.
Mubeena Mariyath P. M.
TKTasneem Kausar
Tasneem Kausar
FHFakhrul Hoda
Fakhrul Hoda
Mehdi H ShahiMehdi H Shahi
Mehdi H Shahi

18 March 2022
Verified
Book Chapter
Closed access
Swalih P AhmedSwalih P Ahmed
Swalih P Ahmed
MSMehdi H. Shahi
Mehdi H. Shahi
MAMohammad Afzal
Mohammad Afzal
AAAsif Ali
Asif Ali

19 March 2026 in Annals of Neurosciences
Verified
Journal Article
Open access
Swalih P AhmedSwalih P Ahmed
Swalih P Ahmed
IAIntezar Ali
Intezar Ali
Mehdi H ShahiMehdi H Shahi
Mehdi H Shahi
Background: Cadmium, a toxic heavy metal, poses a significant risk to human health. Its potential to contribute to brain tumorigenesis is a growing concern. Brain tumours are notoriously difficult to treat due to their aggressive nature, poor prognosis and resistance to conventional therapies. Purpose: To investigate the impact of cadmium exposure on brain tumour development, focusing on its influence on the Sonic Hedgehog (SHH)–glioma-associated oncogene 1 (GLI1) signalling pathway and the stem cell marker B cell-specific Moloney murine leukaemia virus integration site 1 (BMI1). Methods: A total of 25 Wistar rats of 200–250 g body weight range were classified into five groups: Test groups one and two were orally administered with cadmium chloride in drinking water (30 mg/L, 60 mg/L). Positive controls one and two were administered orally with zinc in drinking water (30 mg/L and 60 mg/L) and the negative control group rats received double-distilled water continuously for 28 days. We calculated the rat’s water intake each week. From the third to the fourth week, we observed behavioural changes using an open field test (OFT). The animals were sacrificed on day 29. Thereafter, the brain and hindbrain were separated for further assessment, including real-time reverse transcription polymerase chain reaction (RT-PCR) to measure gene expression levels of key genes in the SHH–GLI1 signalling pathway and stem cell markers. Results: Water intake decreased in both the test and the positive control groups. The OFT analysis revealed significant behavioural changes in all parameters of both the test and positive control groups compared to the negative control group, including movement patterns, speed, travel distance, activity levels and freezing behaviour. Gene expression indicates increased SHH, GLI1, BMI1 and tumour protein 53 (TP53) expression in both the test and positive control groups. Conclusion: Cadmium exposure may initiate and promote brain tumour development by regulating SHH, GLI1, BMI1 and TP53. This may disrupt the normal regulatory mechanisms of the SHH–GLI1 pathway.